All In Biotech

Drug Trial Radar · NCT00025363

Comparison of Chemotherapy Regimens in Treating Children With Relapsed or Progressive Rhabdomyosarcoma

A Groupwide Randomized Phase II Window Study of Two Different Schedules of Irinotecan in Combination With Vincristine And Pilot Assessment of Safety and Efficacy of Tirapazamine Combined With Multiagent Chemotherapy for First Relapse or Progressive Disease in Rhabdomyosarcoma and Related Tumors

Last checked: Nov 19, 2026Latest source record: Jan 17, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

150

Actual

Start

Nov 2001

Primary completion

Oct 2007

Sponsor

Sponsor type
NIH
First posted
Jan 27, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, up to 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Randomized phase II trial to compare the effectiveness of different combination chemotherapy regimens in treating children who have rhabdomyosarcoma. Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells

Conditions

  • Alveolar Childhood Rhabdomyosarcoma
  • Embryonal Childhood Rhabdomyosarcoma
  • Embryonal-botryoid Childhood Rhabdomyosarcoma
  • Previously Treated Childhood Rhabdomyosarcoma
  • Recurrent Childhood Rhabdomyosarcoma

Interventions

  • vincristine sulfateDrug

    Given IV

  • irinotecan hydrochlorideDrug

    Given IV

  • cyclophosphamideDrug

    Given IV

  • doxorubicin hydrochlorideDrug

    Given IV

  • ifosfamideDrug

    Given IV

  • etoposideDrug

    Given IV

  • tirapazamineDrug

    Given IV

  • filgrastimBiological

    Given SC

  • sargramostimBiological

    Given SC

  • pharmacological studyOther

    Correlative studies

  • pharmacogenomic studiesOther

    Correlative studies

  • laboratory biomarker analysisOther

    Correlative studies

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Response at week 6 of investigational window therapy (unfavorable risk patients)Time frame: At week 6
  2. Incidence of DLT when tirapazamine is given in combination with cyclophosphamide and doxorubicin, graded according to the NCI CTC v 2.0Time frame: Up to 6 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Children's Oncology Group

    Arcadia, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.